Merck Stock Declines Following Summit's Cancer Drug Success Over Keytruda

Reported about 1 month ago

Merck & Co. (MRK) shares fell in pre-market trading after a study indicated that Summit Therapeutics' lung cancer drug ivonescimab outperformed Merck's Keytruda. Analysts Seana Smith and Brad Smith provide insights on this development.

You may also interested in these wikis

China's Stocks Slip as Asian Markets Rally

CRFB President Discusses Implications of 2025 for US Debt Ceiling

Strategist Sees Few Vulnerabilities in Current Bull Market

NXP Semiconductors Upgraded by UBS with Higher Price Target

Wall Street Gains as Investors Eye Inflation and Earnings Reports

Rising Demand for Gold Bars at Costco

DOJ Declares Fisker's Recall Repair Charges to Customers Illegal

FBI Launches ‘NexFundAI’ Crypto Token to Combat Market Manipulation

Honeywell Plans to Spin Off Advanced Materials Unit Valued Over $10 Billion

Companies Adjust Strategies Amid Hurricane Threats

Back to all Wikis